These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30703770)

  • 21. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
    Fazio N; Spada F; Giovannini M
    Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
    Riesco-Martinez MC; Capdevila J; Alonso V; Jimenez-Fonseca P; Teule A; Grande E; Sevilla I; Benavent M; Alonso-Gordoa T; Custodio A; Anton-Pascual B; Hernando J; Polo E; Castillo-Trujillo OA; Lamas-Paz A; Teijo A; Rodriguez-Gil Y; Soldevilla B; Garcia-Carbonero R
    Nat Commun; 2024 Aug; 15(1):6753. PubMed ID: 39117670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
    Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
    Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
    Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
    Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
    Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.
    Yilmaz U; Polat G; Anar C; Halilcolar H
    Indian J Cancer; 2011; 48(4):454-9. PubMed ID: 22293260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
    Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
    Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
    Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
    Atagi S; Furuse K; Kawahara M; Kodama N; Ogawara M; Kubota K; Matsui K; Kusunoki Y; Masuda N; Takada M; Negoro S; Fukuoka M
    Jpn J Clin Oncol; 1996 Oct; 26(5):316-21. PubMed ID: 8895671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia.
    Frasci G; Comella P; Panza N; De Cataldis G; Del Gaizo F; Pozzo C; Gravina A; Ruffolo P; Cioffi R; Marcatili P; Della Vittoria M; Monfardini S; Comella G
    Eur J Cancer; 1998 Oct; 34(11):1710-4. PubMed ID: 9893657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    Gupta A; Duque M; Saif MW
    JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
    Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
    Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
    Hadoux J; Malka D; Planchard D; Scoazec JY; Caramella C; Guigay J; Boige V; Leboulleux S; Burtin P; Berdelou A; Loriot Y; Duvillard P; Chougnet CN; Déandréis D; Schlumberger M; Borget I; Ducreux M; Baudin E
    Endocr Relat Cancer; 2015 Jun; 22(3):289-98. PubMed ID: 25770151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):7-10. PubMed ID: 9007113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.